GnRH agonist protokol IVF sikluslarında GnRH antagonist protokol kadar etkin midir?

Giriş ve Amaç:İn vitro fertilizasyon-embriyo transferi( IVF-ET ) uygulanan 1000 siklusun GnRH antagonist veagonist protokollerinin etkinliğinin karşılaştırılması amaçlanmıştır.Gereç ve Yöntemler:Retrospektif tarama ile 1000 siklus çalışmaya dahil edilmiştir, bu siklusların 283’üne agonistprotokol, 717’sine antagonist protokol uygulanmıştır.Bulgular:Antagonist protokol grubunda günlük kullanılan ortalama gonadotropin dozu 249±82,87 IU vesiklus iptal oranları anlamlı derecede yüksekti (p

Is GnRH agonist protocol as effective as GnRH antagonist protocol in IVF cycles?

Objective Aim of this study is to compare effectiveness of gonadotrophin releasing hormone (GnRH) agonist in-vitro fertilisation(IVF) cycles compared to GnRH antagonist IVF cycles. MethodsPatient’s records were retrospectively evaluated 283 GnRH agonist and 717 GnRH antagonist fresh cycles were compared. Results Daily dose of gonadotrophin (249±82,87) and cycle cancellation rates were more common in GnRH antagonist group (p

PDF

___

1. Gnoth C, Godehardt D, Godehardt E, Frank-Herrmann P, Freundl G. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod 2003;18: 1959-66.
2. Vayena E, Rowe PJ,P.Griffin PD. Current Practices and Controversies in Assisted Reproduction. WHO Press 2002;83-101.
3. Steptoe PC, Edwards RG. Reimplantation of a human embryo with subsequent tubal pregnancy. Lancet;1976;31:750-751.
4. Steptoe PC, Edwards RG. Birth after reimplantation of a human embryo. Lancet;1978;12;2:366.
5. Janssens RM, Brus L,Cahill DJ,Huirne JA,Schoemaker J,Lambalk CB. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000;6:505-18.
6. ART factsheet. European Society of Human Reproduc tion and Embryology. 2014.
7. Daya S, Maheshwari A, Siristatidis CS, Bhattacharya S, Gibreel AF. Gonadotropin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertiliza tion and gamete intrafallopian transfer cycles. Cochrane Database Systematic Review, 2000;(2):CD001299.
8. Sunkara SK, Coomarasamy A, Faris F,Braude P, Khalaf Y. Long gonadotropn-releasing hormone agonist versus short agonist versus antagonist regimens in poorrespond ers undergoing in in vitro fertilization: a randomized controlled trial. Fertil Steril 2014; 101(1):147–153.
9. Albuquerque LE, Tso LO, Saconato H, Albuquerque MC, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;1:CD002808.
10. Assisted Reproductive Technology National Summary Report. National Center for Chronic Disease Prevention and Health Promotion.2012;1:82 (https://www.cdc.gov /art/pdf/2012-report/art-2012-fertility-clinic-report.pdf).
11. CARTR Plus 2013 Report. The Canadian Assisted Repro ductive Technologies Register(CARTR). (https://cfas. ca/cartr-annual-reports.html).
12. Wang YA, Healy D, Black D, Sullivan AD. Age-specific success rate for women undertaking their first assisted reproduction technology treatment using their own oocytes in Australia, 2002– 2005. Hum Reprod. 2008; 23(7):1633-8.
13. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S. Predictive factors in in vitro fertiliza tion(IVF) : a systematic review and meta-analysis. Hum Reprod Update. 2010;16(6):577-89.
14. Gesink Law DC, Maclehose RF, Longnecker MP. Obesi ty and time to pregnancy. Hum Reprod 2007;22(2):414–420.
15. Maheshwari A, Stofberg L, Bhattacharya S. Effect of overweight and obesity on assisted reproductive technol ogy—a systematic review. Hum Reprod Update 2007;13(5):433–444.
16. Griesinger G, Felberbaum R, Diedrich K. GnRH antago nists in ovarian stimulation:a treatment regimen of clinicians' second choice? Data from the German nation al IVF registry. Hum Reprod 2005;20(9):2373-75.
17. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonado trophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007:14(5):640-9.
18. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimu lation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrore lix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15(3):526–531.
19. Al Inany HG, Youssef MAFM, Aboulghar M, Broek mans FJ, Sterrenburg MD, Smit JG, Abou‐Setta AM. Gonadotrophin‐releasing hormone antagonists for assist ed reproductive technology. Cochrane Database of Systematic Reviews 2011;5:CD001750.
20. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-anal ysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reproductive BioMedicine Online 2012;24:6-22.
21. Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antag onist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014;9(9):e106854.
22. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12(2),159–168.
23. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213–1220.
24. Youssef MAFM, Van der Veen F, Al‐Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboul foutouh I, van Wely M. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews 2014;10:CD008046.
25. Humaidan P, Polyzos NP. Human chorionic gonadotro pin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology—“The king is dead, long live the king!”. Fertil Steril 2014;102(2):339-341
26. The European and Middle East Orglutron Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptore lin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16(4): 644-51.
27. Kolibianakis M, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotropins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12(6):651-71.
28. Badrawi A, Al-Inany H, Hussein M, Zaki S, Ramzy AM. Agonist versus antagonist in ICSI cycles :a randomized trial and cost effectiveness analysis. Middle East Society Journal 2005;10(1):49-54.
29. Xavier P, Gamboa C, Calejo L, et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busere line) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol. 2005;120(2):185–189
30. Luo S, Li S, Li X, Bai Y, Jin S. Effect of gonadotropin-re leasing hormone antagonists on intrauterine insemination cycles in women with polycystic ovary syndrome: a meta-analysis. Gynecological Endocrinology 2014;30(4):255-259.
31. Al-Inany H, Aboulghar MA. GnRH antagonist in assist ed reproduction Cochrane systematic review. Hum Reprod 2002;17(4):874-85.
32. Practice Committee of the American Society for Repro ductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):44–50.
33. Schally AV, Arimura A, Kastin AJ. Gonadotropin-re leasing hormone:one polypeptide regulates secretion of luteinizing and follicle stimulating hormones. Science 1971;173:1036-8.
34. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90(3):188-93.